Sildenafil (Revatio®)

Assessment Status Rapid Review Complete
Drug Sildenafil
Brand Revatio®
Indication (a) For the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. (b) For the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension.
Assessment Process
Rapid review commissioned 16/04/2014
Rapid review completed 23/05/2014
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended